Can GLP-1 Cause Diabetes? Clinical Evidence & Safety

Last reviewed: May 22, 2026

Last updated: May 22, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

No, GLP-1 agonists do not cause diabetes. These medications actively lower blood sugar by stimulating insulin secretion and improving insulin sensitivity. In fact, GLP-1 agonists are a cornerstone of type 2 diabetes treatment and have been shown to reduce hemoglobin A1c (HbA1c) by 1.5-2.0 percentage points in clinical trials.

The confusion often stems from unfamiliarity with how GLP-1 works and misconceptions about injectable medications. Understanding the mechanism, your baseline health status, and how genetic factors in your GLP-1 receptor pathway may influence response can help you and your provider make informed decisions about whether GLP-1 therapy is appropriate for you.

How GLP-1 Agonists Regulate Blood Sugar—Not Raise It

GLP-1 (glucagon-like peptide 1) is a natural hormone your intestines release after eating. GLP-1 agonists mimic this hormone, binding to GLP-1 receptors in the pancreas and brain. This triggers insulin secretion when blood glucose is elevated, suppresses glucagon (which raises glucose), and slows gastric emptying to reduce blood sugar spikes.

The mechanism is fundamentally glucose-dependent: insulin is released only when blood sugar is high. This reduces hypoglycemia risk compared to some older diabetes medications. Studies show GLP-1 agonists improve cardiovascular outcomes and reduce weight, making them one of the most evidence-supported diabetes therapies available.

Clinical Evidence: GLP-1 Safety Profile & Diabetes Risk

Large randomized controlled trials—LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide)—demonstrate GLP-1 agonists do not cause new-onset diabetes or worsen glucose control in non-diabetic individuals. Among people with type 2 diabetes, they consistently lower HbA1c and reduce mortality and cardiovascular events. The concern about causing diabetes is not supported by clinical evidence.

Clinical Outcome	GLP-1 Agonist Effect
Blood glucose (fasting)	Typically decreases 10–40 mg/dL
HbA1c reduction	1.5–2.0 percentage points in type 2 diabetes
Hypoglycemia risk	Low when used alone; higher risk with insulin or sulfonylureas
Cardiovascular events	Reduced by 12–26% in major trials (LEADER, SUSTAIN-6)
New-onset diabetes risk	Not increased; may prevent progression to diabetes in prediabetic patients

Who Should and Shouldn't Use GLP-1 Agonists: Provider Evaluation Framework

Your provider evaluates several factors before recommending GLP-1 therapy: fasting glucose, HbA1c, kidney function (eGFR), gastrointestinal history, personal or family history of thyroid cancer or multiple endocrine neoplasia type 2 (MEN-2), and medication interactions. GLP-1 agonists are appropriate for type 2 diabetes, prediabetes with obesity, and cardiovascular disease risk reduction—not for type 1 diabetes or acute illness.

Contraindications include personal or family history of medullary thyroid carcinoma, MEN-2, severe pancreatitis, or severe kidney disease (eGFR < 15 mL/min/1.73m²). Relative cautions include pregnancy, thyroid nodules, and diabetic retinopathy requiring close monitoring. Your provider will determine suitability based on your complete medical history and labs.

Biomarkers, Genetics, and Personalized GLP-1 Response

Beyond traditional labs (glucose, A1c, lipids), emerging evidence suggests genetic variations in the GLP-1 receptor (GLP1R) and GIPR genes may influence medication response and side-effect tolerance. Individuals with certain variants may experience greater glucose-lowering or more pronounced gastrointestinal effects. These predispositions do not determine outcome but can support a more personalized conversation with your provider.

PlexusDx's Precision Peptide Genetic Test examines variants including GLP1R rs6923761 and GIPR rs1800437, which relate to GLP-1 pathway function. The test may help provide context for why one GLP-1 agonist or dosing strategy might suit you better than another. Results should be interpreted with your qualified healthcare provider as part of a comprehensive evaluation—genetics inform probability, not guarantee.

How PlexusDx Supports a More Personalized Approach

PlexusDx recognizes that genetic variation in GLP-1 receptor pathways can influence how efficiently your body processes GLP-1 agonists. By identifying predispositions in genes like GLP1R and GIPR, the Precision Peptide Genetic Test may help provide context for your individual response profile. This information, combined with your clinical labs and provider assessment, supports a more tailored treatment conversation.

The Precision Peptide Genetic Test reveals your genetic predispositions in peptide signaling pathways, including GLP-1 receptor variants and glucose metabolism genes (e.g., FTO rs9939609). These predispositions do not predict exact medication response or guarantee outcomes—they identify areas where your physiology may diverge from population averages. Your provider can use this data to inform dosing, formulation choice (injection vs. oral), and monitoring strategy.

Understanding your genetic context alongside your clinical history, labs, and symptoms can support a more informed conversation with your provider about whether GLP-1 therapy, and which type, is right for you. PlexusDx compounded GLP-1 options (semaglutide injection, tirzepatide injection, oral formulations, and dual-compound protocols) are available through licensed 503A pharmacies, allowing your provider flexibility in personalizing your treatment plan.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

If GLP-1 medications lower blood sugar, why do people still worry they might trigger diabetes?

The article traces the worry to unfamiliarity with how GLP-1 works and to general misconceptions about injectable medications, not to any clinical finding. It states plainly that GLP-1 agonists lower blood sugar by stimulating insulin secretion and improving insulin sensitivity, and that they are a cornerstone of type 2 diabetes treatment. The post says the concern about causing diabetes is not supported by clinical evidence.

Why does this post say hypoglycemia stays unlikely unless another diabetes drug is in the picture?

Because the mechanism is glucose-dependent: the post explains that insulin is released only when blood glucose is already elevated, which lowers hypoglycemia risk compared with some older diabetes medications. Its outcomes table reinforces this, listing hypoglycemia risk as low when a GLP-1 is used alone but higher when it is combined with insulin or sulfonylureas. That combination is where the article says monitoring matters most.

What did LEADER, SUSTAIN-6 and REWIND show about new-onset diabetes in people who did not already have it?

The post cites those three large randomized controlled trials, covering liraglutide, semaglutide and dulaglutide, as evidence that GLP-1 agonists do not cause new-onset diabetes or worsen glucose control in people without diabetes. Among participants who did have type 2 diabetes, the article says the same trials consistently showed lower HbA1c along with reduced mortality and cardiovascular events.

Which kidney number does the article name as a hard stop for GLP-1 therapy?

The post lists severe kidney disease defined as an eGFR below 15 mL/min/1.73m2 among its contraindications, alongside personal or family history of medullary thyroid carcinoma, MEN-2, and severe pancreatitis. Kidney function is also one of the factors the article says a provider reviews up front, together with fasting glucose, HbA1c, gastrointestinal history and medication interactions.

Does the article consider GLP-1 agonists appropriate for type 1 diabetes?

No. The post explicitly says GLP-1 agonists are appropriate for type 2 diabetes, prediabetes with obesity, and cardiovascular risk reduction, but not for type 1 diabetes or acute illness. It also flags pregnancy, thyroid nodules and diabetic retinopathy as relative cautions requiring close monitoring, and leaves the final suitability judgment to a provider reviewing the full medical history and labs.

Related Reading

• Role Of Glp 1 In Blood Sugar Control And Diabetes Treatment
• Glp 1 For Type 2 Diabetes
• Glp Receptor 1 Agonists
• Glp 1 Receptor Agonists For Weight Loss

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.